Clinical relevance of a European collaborative study on comparative susceptibility of Gram-positive clinical isolates to teicoplanin and vancomycin

International Journal of Antimicrobial Agents

Volumn 10, Issue 4, 1998, Pages 271-277

  Gruneberg R N ^a   Hryniewicz, W ^b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b Sera & Vaccines Central Research Laboratory Warszawa   (Poland)

Author keywords

Glycopeptides; Mueller Hinton medium; Nosocomial problems; Teicoplanin resistant

Indexed keywords

TEICOPLANIN; VANCOMYCIN;

ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GASTROINTESTINAL INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS HAEMOLYTICUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; EUROPE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LABORATORIES; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL; TEICOPLANIN; VANCOMYCIN;

EID: 0344026341     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(98)00050-8     Document Type: Article

References (38)

1. Cookson B. Aspects of the epidemiology of MRSA in Europe, J Chemother 1995;7 Suppl 3:93-98.
2. Trzcinski K, Hryniewicz W, Claus H, Witte W Characterization of two different clusters of clonally related methicillin-resistant Staphylococcus aureus strains by conventional and molecular typing. J Hosp Infect. 28(2):1994;113-126.
3. Christensen GD, Baldassarri L, Simpson WA. Colonisation of medical devices by Coagulase-Negative Staphylococci. In: Bisno AL, Waldvogel FA, editors. Infections Associated with Indwelling Medical Devices. Washington: American Society for Microbiology, 1994:45-78.
4. Low DE, Schmidt BK, Kirpalani HM et al. An endemic strain of Staphylococcus haemolyticus colonizing and causing bacteremia in neonatal intensive care unit patients. Pediatrics. 89:1992;696-700.
5. Ponce de Leon S, Guenthner SH, Wenzel RP Microbiologic studies of coagulase-negative staphylococci isolated from patients with nosocomial bacteraemias. J Hosp Infect. 7:1986;121-129.
6. Dekker AW, Rozenberg-Arska M, Verhoef J et al. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med. 106:1987;7-11.
7. Hurley JC Prophylaxis with enteral antibiotics in ventilated patients: selective decontamination or selective cross-infection? Antimicrob Agents Chemother. 39:1995;941-947.
8. McGowan JE Jr, Metchock BG. Penicillin-resistant pneumococci-an emerging threat to successful therapy, J Hosp Infect 1995;30 Suppl:472-482.
9. Baquero F. Trends in antibiotic resistance of respiratory pathogens: analysis and commentary on a collaborative study, J Antimicrob Chemother 1996;38 Suppl A:117-132.
10. Rowland M Clinical pharmacokinetics of teicoplanin. Clin Pharmacokin. 18:1990;184-209.
11. Beauregard DA, Williams DH, Gwynn MN, Knowles DJ Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob Agents Chemother. 39:1995;781-785.
12. Felmingham D, Solomonides K, O'Hare MD, Wilson A, Rowland M Clinical pharmacokinetics of teicoplanin. Clin Pharmacokin. 18:1990;184-209.
13. Jean Pierre H, Riviere M, Darbas H, Boyer G In vitro activity of glycopeptides on 114 coagulase-negative staphylococci: problems with the teicoplanin diffusion test, alert parameters indicating need for MIC determination. Pathol Biol. 41:1993;531-536.
14. Goldstein FW, Coutrot A, Sieffer A, Acar JF Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother. 34:1990;899-900.
15. Mainardi JL, Shlaes DM, Goering RV et al. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J Infect Dis. 171(6):1995;1646-1650.
16. Jones RN, Sader HS, Erwin ME, Anderson SC Emerging multiply resistant enterococci among clinical isolates I prevalence data from 97 medical center surveillance study in the USA. Enterococcus study group. Diagn Microbiol Infect Dis. 21(2):1995;85-93.
17. Miele A, Bandera M, Goldstein BP Use of primers selective for vancomycin resistance genes to determine van genotype in enterococci and to study gene organization in VanA isolates. Antimicrob Agents Chemother. 39:1995;1772-1778.
18. Perichon B, Reynolds P, Courvalin P VanD-type glycopeptide-resistant Enterococcus faecium BM 4339. Antimicrob Ag Chemother. 41(9):1995;2016-2018.
19. NCCLS-National Committee of Clinical Laboratory Standards. Methods of Dilution Susceptibility Tests for Bacteria that Grow Aerobically. 3rd ed. Approved Standard. NCCLS 1993 Document M7-A3 (ISBN 1-56238-209-8). NCCLS. 771 East Lancaster Avenue, Villanova, PA 19085, USA.
20. Brown DFJ, Courvalin P European glycopeptide resistance group: quality assessment of glycopeptide susceptibility tests: a European collaborative study. Int J Antimicrob Ag. 9:1998;153-163.
21. Baquero F, Martinez-Beltran J, Loza E, et al. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe, J Antimicrob Chemother 1991;28 Suppl C:31-38.
22. Schmitz FJ, Kitzrow M, Haupt C et al. Antimicrobial susceptibility and typing of coagulase-negative Staphylococci from different intensive care units. Klin Labor. 42(5):1996;403-410.
23. Cox RA, Conquest C, Mallaghan C, Marples RR A major outbreak of methicillin-resistant Staphylococcus aureus caused by a new phage-type (EMRSA-16). J Hosp Infect. 29:1995;87-106.
24. Krcmery V Jr, Trupl J, Drgona L, Lacka J, Kukuckova E, Oravcova E Nosocomial bacteremia due to vancomycin-resistant Staphylococcus epidermidis in four patients with cancer, neutropenia and previous treatment with vancomcyin. Eur J Clin Microbiol Infect Dis. 15:1996;259-260.
25. Leclerq R, Derlot E, Weber M, Duval J, Courvalin P Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob Agents Chemother. 33:1989;10-15.
26. Noble WC, Virani Z, Cree RG Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Letters. 72:1992;195-198.
27. Krcmery V Jr, Spanik S, Trupl J First report of vancomycin-resistant Streptococcus mitis bacteremia in a leukemic patient after prophylaxis with quinolones and during treatment with vancomyin. J Chemother. 8:1996;325-326.
28. Calain P, Krause KH, Vaudaux P et al. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis. 155:1987;187-191.
29. Galanakis N, Giamarellou H, Vlachogiannis N, Dendrinos C, Daikos GK Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections. Eur J Clin Microbiol Infect Dis. 7:1988;130-134.
30. Harding I, Garaud JJ. Teicoplanin in the treatment of infections caused by coagulase-negative staphylococci, J Antimicrob Chemother 1988; 21 Suppl A:93-103.
31. Wilson APR, Grüneberg RN, Neu H Dosage recommendations for teicoplanin. J Antimicrob Chemother. 32:1993;792-796.
32. Greenberg RN Treatment of bone, joint, and vascular-access-associated Gram-positive bacterial infections with teicoplanin. Antimicrob Agents Chemother. 34:1990;2392-2397.
33. Wood MJ The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother. 37:1996;209-222.
34. Aslangul E, Barros-Baptista M, Fantin B, Arthur M, Courvalin P, Carbon C. Evaluation of the activity of vancomycin (Vm) and teicoplanin (Te) in experimental endocarditis due to Enterococcus faecalis with a vanB phenotype, ICAAC 1995;B115(Abstact).
35. Aslangul E, Barros-Baptista M, Fantin B, Arthur M, Courvalin P, Carbon C. Emergence of high-level glycopeptide resistance in vanB-type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis, ICAAC 1996;B005(Abstract).
36. Blumberg EA, Mandler HD, Fuchs AE, Molavi J, Reboli AC, Wood CA. Efficacy and toxicity of Synercid (Quinupristin/Dalfopristin) [SYN (Q/D)] for vancomycin-resistant Enterococcus faecium (VREF) infections, ICAAC 1996;L032(Abstract).
37. Linden P, Pasculle AW, McDevitt D, Dotterweich L. Emergence of superinfection with Enterococcus faecalis during RP 59500; treatment of vancomycin-resistant Enterococcus faecium infection (VREF), ICAAC 1996;L031(Abstract).
38. Graninger W, Wenisch C, Wiesinger E et al. Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis. Eur J Clin Microbiol Infect Dis. 14:1995;643-647.